Prospects for the development of epigenetic drugs for CNS conditions.
about
Where Do Epigenetics and Developmental Origins Take the Field of Developmental Psychopathology?Microbiota and Neurological Disorders: A Gut Feeling.The dynamic epigenome and its implications for behavioral interventions: a role for epigenetics to inform disorder prevention and health promotionAdvanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the BrainDiscovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisEpigenetics and therapeutic targets mediating neuroprotection"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Annual Research Review: DNA methylation as a mediator in the association between risk exposure and child and adolescent psychopathology.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.Toward development of epigenetic drugs for central nervous system disorders: Modulating neuroplasticity via H3K4 methylation.Epigenetic Mechanisms in Psychiatric Diseases and Epigenetic Therapy.DNA Methyltransferase Inhibitors: Development and Applications.Epigenetic and transgenerational mechanisms in infection-mediated neurodevelopmental disorders.CDYL suppresses epileptogenesis in mice through repression of axonal Nav1.6 sodium channel expression.Aberrant cognitive phenotypes and altered hippocampal BDNF expression related to epigenetic modifications in mice lacking the post-synaptic scaffolding protein SHANK1: Implications for autism spectrum disorder.Epigenetic Advances in Behavioral and Brain Sciences have Relevance for Public Policy.A Methylome-Wide Association Study of Trajectories of Oppositional Defiant Behaviors and Biological Overlap With Attention Deficit Hyperactivity Disorder.Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells.GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women.
P2860
Q24289474-4EEA6F9F-B439-41EA-991E-7A413ED19921Q24570085-06DB175C-36C9-408D-9431-E6512E0B039EQ26751394-C1CA4657-FA38-4A22-BAE8-7A87B3DE7C2FQ26770355-769ABE10-4591-497B-AD27-391C382C6767Q27728041-1A47AD57-FF98-4FC4-91D2-9BD0CC8D2EA7Q28080633-7FF98ECA-9DDD-4F83-BF9D-6B193350C6F3Q28595570-92E7CBC8-5015-4D82-835D-9A88C24286BFQ38652894-9808DAFF-E7CA-40B3-A92D-ED7E50746D33Q38742951-45419A8D-930A-4589-944E-AF2ACFF383C5Q38743021-0C137489-C950-4FBA-BDA1-9B26B538B628Q38916715-08B783C9-C696-4BDF-8832-8E77EEFFB6C4Q38946328-25C20147-B236-42EC-B18B-CA925F1A209FQ39003558-C6E96D47-D468-41E9-8BFA-8F9877C52EE1Q39277989-1BBFDD16-43B2-41CC-BFEE-EB20D0D105F2Q41527518-F4420BE3-B50B-4AB3-BD59-D163BEA574A2Q47872240-0EE305B3-1E4E-4F96-8931-19ED8E141074Q47935671-F8A711D1-0354-4C1D-AF0B-BD0B4A7C8B3AQ50000961-0EDF9277-3572-4F61-B64F-EC215F8093E4Q52655847-238B1B75-7CA5-4AA7-B618-FA8277CAD3E1Q53428761-C1A58075-8EBB-49DF-86BC-4196E00F8482Q55369867-F0B41AC4-D474-467C-BC3E-345F612B08DB
P2860
Prospects for the development of epigenetic drugs for CNS conditions.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prospects for the development of epigenetic drugs for CNS conditions.
@en
type
label
Prospects for the development of epigenetic drugs for CNS conditions.
@en
prefLabel
Prospects for the development of epigenetic drugs for CNS conditions.
@en
P2860
P356
P1476
Prospects for the development of epigenetic drugs for CNS conditions.
@en
P2093
Moshe Szyf
P2860
P2888
P304
P356
10.1038/NRD4580
P577
2015-05-22T00:00:00Z
P6179
1020358042